April 24, 2025

FDA Warns of Topical Finasteride Risks

The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

September 17, 2024

Can Hair Dye Cause Retinopathy?

Aromatic amines may cause long-term RPE dysfunction

Conexiant

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

January 07, 2025

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.

Conexiant

July 31, 2024

Alopecia Areata Linked to Mental, Autoimmune Risks

New study published in JAMA Dermatology reveals that patients newly diagnosed with alopecia areata face a higher risk of developing psychiatric and autoimmune disorders.

Conexiant

February 07, 2025

Hematologic Indicators Linked to Alopecia Areata Severity

Researchers analyze hematological ratios in alopecia areata severity assessment.

Conexiant

October 11, 2024

Skin Pigmentation: Rethinking Drug Efficacy

With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.

Conexiant

November 26, 2024

Do Cancer Drugs Trigger Skin Issues?

A recent analysis reveals that nearly 50% of significant dermatologic adverse events linked to anticancer therapies are associated with targeted therapies, with rash, dry skin, and alopecia being the most commonly reported adverse events.

Conexiant